孕早期最大滋养层厚度联合母血及尿生物标志物无创产前诊断先天性巨细胞病毒感染
本研究为回顾性队列研究,纳入2019年10月至2024年5月期间转诊至Necker-Enfants malades医院的127例孕早期母体原发性巨细胞病毒感染孕妇,评估孕早期三维超声测量的最大滋养层厚度(MTT)联合母体生物标志物对CMV垂直传播的早期预测价值。结果显示,羊水CMV-PCR阳性者MTT显著高于阴性者(中位数21.3 mm vs 17.1 mm,P=0.017),MTT最佳阈值为19.0 mm,联合母血CMV-PCR阳性及伐昔洛韦启动延迟超过10周时,预测羊水CMV-PCR阳性的AUC为0.94。
要点
- 孕早期三维超声测量的最大滋养层厚度(MTT)在羊水CMV-PCR阳性者中显著高于阴性者(中位数21.3 mm vs 17.1 mm,P=0.017)。
- MTT预测垂直传播的最佳阈值为19.0 mm,敏感度为83.33%(95% CI,62.25-100%)。
- MTT联合母血CMV-PCR阳性及伐昔洛韦启动延迟超过10周,预测羊水CMV-PCR阳性的AUC为0.94(95% CI,0.87-0.99)。
核心结论
- 孕早期三维超声测量的最大滋养层厚度(MTT)增加与CMV垂直传播相关,可能作为早期无创标志物。
- MTT联合母血CMV-PCR状态及治疗启动时机可提高预测准确性,并可能指导早期咨询和目标性侵入性检查。
研究设计与样本
- 本研究为回顾性队列研究,纳入2019年10月至2024年5月期间转诊至Necker-Enfants malades医院的孕早期CMV母体原发性感染孕妇。
- 排除多胎妊娠及遗传学异常胎儿,最终纳入127例孕妇,中位CMV-MPI孕龄为2.0周(四分位距,-2.5至7.0周)。
- MTT由两名独立观察者在孕11+0至14+6周使用三维多平面超声测量,采用组内相关系数(ICC)评估观察者间一致性。
- 记录母体特征,包括孕早期母体生物标志物(妊娠相关血浆蛋白-A、游离β-人绒毛膜促性腺激素和胎盘生长因子)及母血和尿CMV聚合酶链反应(PCR)状态。
- 垂直传播通过绒毛膜绒毛(CV)和/或羊水(AF)的CMV-PCR确认,采用逻辑回归模型和受试者工作特征(ROC)曲线分析评估MTT单独及联合相关协变量的预测价值。
主要发现
- 120例(94.5%)孕妇接受伐昔洛韦进行二级预防。
- CV样本CMV-PCR阳性率为7.1%(采样中位孕龄13.7周),AF样本阳性率为9.4%(采样中位孕龄17.4周)。
- 羊水CMV-PCR阳性者MTT中位数为21.3 mm,阴性者为17.1 mm,差异显著(P=0.017)。
- MTT测量的ICC为0.827(95% CI,0.763-0.875),表明观察者间重复性良好。
- ROC曲线分析确定MTT最佳阈值为19.0 mm,预测垂直传播的敏感度为83.33%(95% CI,62.25-100%)。
临床怎么用
- 作者认为,孕早期三维超声测量的MTT增加与CMV垂直传播相关,可能作为早期无创标志物。
- 作者认为,MTT联合母血CMV-PCR状态及治疗启动时机可提高预测准确性,并可能指导早期咨询和目标性侵入性检查。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Congenital cytomegalovirus (CMV) infection, a leading cause of sensorineural hearing loss and neurological impairment, is typically diagnosed by second-trimester amniocentesis, delaying clinical decision-making. This study aimed to assess the predictive value of maximum trophoblast thickness (MTT) measured by first-trimester three-dimensional (3D) ultrasound, in combination with maternal biomarkers, for the early prediction of CMV vertical transmission. METHODS: This was a retrospective cohort study of pregnant women, not previously seropositive for CMV, who were referred to Necker-Enfants malades Hospital between October 2019 and May 2024 for maternal primary infection (MPI) with CMV in early pregnancy. Multiple pregnancies and fetuses with genetic anomaly were excluded. MTT measurement was performed using 3D multiplanar ultrasound between 11 + 0 and 14 + 6 weeks' gestation by two independent observers. Interobserver agreement for MTT measurement was assessed using the intraclass correlation coefficient (ICC). We recorded maternal characteristics, including first-trimester maternal biomarkers (pregnancy-associated plasma protein-A, free β-human chorionic gonadotropin and placental growth factor) and CMV polymerase chain reaction (PCR) status in the maternal blood and urine. Vertical transmission was confirmed by CMV-PCR in chorionic villi (CV) and/or amniotic fluid (AF). The predictive value of MTT, alone and in combination with relevant covariables, was assessed using logistic regression models and receiver-operating-characteristics (ROC)-curve analysis. RESULTS: A total of 127 pregnant women with a median gestational age (GA) at CMV-MPI of 2.0 (interquartile range, -2.5 to 7.0) weeks were included, of whom 120 (94.5%) received valacyclovir for secondary prevention. CMV-PCR was positive in 7.1% of CV samples (median GA at sampling, 13.7 weeks) and 9.4% of AF samples (median GA at sampling, 17.4 weeks). MTT was significantly higher in cases with a positive CMV-PCR result in AF compared to those with a negative result (median, 21.3 mm vs 17.1 mm; P = 0.017). The ICC for MTT measurement was 0.827 (95% CI, 0.763-0.875), indicating good interobserver reproducibility. ROC-curve analysis identified 19.0 mm as the optimal MTT threshold, yielding a sensitivity of 83.33% (95% CI, 62.25-100%) for predicting vertical transmission. When combined with CMV-PCR positivity in the maternal blood in the first trimester and delayed valacyclovir initiation beyond 10 weeks, the predictive model achieved an area under the ROC curve of 0.94 (95% CI, 0.87-0.99) for CMV-PCR positivity in AF, with a sensitivity of 80.00% (95% CI, 44.39-97.48%), specificity of 93.26% (95% CI, 85.90-97.49%), positive predictive value of 57.14% (95% CI, 36.71-75.40%) and negative predictive value of 97.65% (95% CI, 92.31-99.31%). CONCLUSION: Increased MTT measured by 3D ultrasound in the first trimester is associated with CMV vertical transmission and may serve as an early non-invasive marker. Combining MTT with CMV-PCR status in the maternal blood and timing at initiation of treatment improves predictive accuracy and could guide early counseling and targeted invasive testing. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Bourgon N, Fernandez M, Chatzakis C, et al. Non-invasive prenatal diagnosis of congenital cytomegalovirus infection using maximum trophoblast thickness and biomarkers in maternal blood and urine in first trimester. Ultrasound Obstet Gynecol. 2025. PMID: 41047886. doi:10.1002/uog.70019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。